Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Synthetic High-Density Lipoprotein-like Nanoparticles (HDL NP) Cause Apoptosis and Enhance Killing By B-Cell Receptor and BCL-2 Inhibitors in Chronic Lymphocytic Leukemia (CLL)

Kaylin Marie McMahon, Cristina Scielzo, Lydia Scarfo, Pamela Ranghetti, Shuo Yang, Leo I. Gordon, MD, Frank Giles, MDMB, Colby Shad Thaxton, MD PhD, Paolo Ghia, MD PhD

Blood (2015) 126 (23): 2949.

https://doi.org/10.1182/blood.V126.23.2949.2949

Published: 2015

Journal Articles

Single-Cell Immune Signatures in Patients with Chronic Phase Chronic Myeloid Leukemia (CML) Treated with Nilotinib: An ENEST1st Sub Study

Blood (2015) 126 (23): 4022.

https://doi.org/10.1182/blood.V126.23.4022.4022

Published: 2015

Journal Articles

Increased TACE (Tumor necrosis factor-alpha±-converting enzyme; ADAM17) Activity Associates with Decreased CD62L Expression, Increased Soluble CD62L Plasma Levels and Predicts Molecular Response to Nilotinib Therapy in Patients with Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP): Results from an ENEST1st Substudy

Sieghart Sopper, PhD, Satu Mustjoki, MD PhD, Angelica Loskog, PhD, Bjorn T. Gjertsen, MD PhD, Guenther A. Gastl, MD, Frank Giles, MDMB, Andreas Hochhaus, MD, Gert J. Ossenkoppele, MD PhD, Kimmo Porkka, MD PhD, Dominik Wolf, MD

Blood (2015) 126 (23): 4033.

https://doi.org/10.1182/blood.V126.23.4033.4033

Published: 2015

Journal Articles

Quantification of BCR-ABL with Digital PCR Results in a Significantly Lower Rate of Deep Molecular Responses When Compared to RT-qPCR in CML Patients Treated in the ENEST1st Trial

Georg-Nikolaus Franke, MD, Jacqueline Maier, PhD, Kathrin Wildenberger, Michael Cross, PhD, Oliver Frank, PhD, Frank Giles, MDMB, Andreas Hochhaus, MD, Christian T. Dietz, PhD, Martin C. Müller, Dietger Niederwieser, MD, Thoralf Lange, MD

Blood (2015) 126 (23): 135.

https://doi.org/10.1182/blood.V126.23.135.135

Published: 2015

Journal Articles

Reduced Expression of CD62L Is Associated with Increased ADAM17 Activity and Predicts Molecular Response to Nilotinib Therapy in Patients with Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP)

Sieghart Sopper, PhD, Satu Mustjoki, MD PhD, Angelica Loskog, PhD, Bjorn T. Gjertsen, MD PhD, Ute Mark, Jens Haenig, Nidas Jurjonas, Gunther Gastl, Prof., Dr., Frank Giles, MDMB, Andreas Hochhaus, MD, Gert J Ossenkoppele, MD PhD, Kimmo Porkka, MD PhD, Dominik Wolf, MD

Blood (2014) 124 (21): 4522.

https://doi.org/10.1182/blood.V124.21.4522.4522

Published: 2014

Journal Articles

Low Level BCR-ABL Mutations and Response to Treatment: A Substudy of the ENEST1st Trial

Georg-Nikolaus Franke, MD, Jacqueline Maier, PhD, Karoline Schubert, Michael Cross, PhD, Sabine Leiblein, Kathrin Wildenberger, Frank Giles, MDMB, Andreas Hochhaus, MD, Oliver Frank, PhD, Dietger Niederwieser, MD, Thoralf Lange, MD

Blood (2014) 124 (21): 3143.

https://doi.org/10.1182/blood.V124.21.3143.3143

Published: 2014

Journal Articles

Prognostic Value of Multi-Drug Resistance 1 Gene (MDR1) Expression in Newly Diagnosed Patients with Chronic Myeloid Leukemia on Nilotinib Treatment—a Subanalysis of the ENEST1st Study

Christian Dietz, PhD, Michael Lauseker, PhD, Benjamin Hanfstein, MD, Philippe Rousselot, MD, Thoralf Lange, MD, Jacqueline Maier, PhD, Letizia Foroni, Gareth Gerrard, Rodica Talmaci, PhD, Jeroen JWM Janssen, MD, Oliver Frank, PhD, Susanne Saussele, MD, Frank Giles, MDMB, Andreas Hochhaus, MD, Martin C. Müller, MD

Blood (2014) 124 (21): 3144.

https://doi.org/10.1182/blood.V124.21.3144.3144

Published: 2014

NARROW

Synthetic High-Density Lipoprotein-like Nanoparticles (HDL NP) Cause Apoptosis and Enhance Killing By B-Cell Receptor and BCL-2 Inhibitors in Chronic Lymphocytic Leukemia (CLL)

Single-Cell Immune Signatures in Patients with Chronic Phase Chronic Myeloid Leukemia (CML) Treated with Nilotinib: An ENEST1st Sub Study

Quantification of BCR-ABL with Digital PCR Results in a Significantly Lower Rate of Deep Molecular Responses When Compared to RT-qPCR in CML Patients Treated in the ENEST1st Trial

Reduced Expression of CD62L Is Associated with Increased ADAM17 Activity and Predicts Molecular Response to Nilotinib Therapy in Patients with Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP)

Low Level BCR-ABL Mutations and Response to Treatment: A Substudy of the ENEST1st Trial

Prognostic Value of Multi-Drug Resistance 1 Gene (MDR1) Expression in Newly Diagnosed Patients with Chronic Myeloid Leukemia on Nilotinib Treatment—a Subanalysis of the ENEST1st Study

Email alerts

ASH Publications

American Society of Hematology

Synthetic High-Density Lipoprotein-like Nanoparticles (HDL NP) Cause Apoptosis and Enhance Killing By B-Cell Receptor and BCL-2 Inhibitors in Chronic Lymphocytic Leukemia (CLL)

Single-Cell Immune Signatures in Patients with Chronic Phase Chronic Myeloid Leukemia (CML) Treated with Nilotinib: An ENEST1st Sub Study

Quantification of BCR-ABL with Digital PCR Results in a Significantly Lower Rate of Deep Molecular Responses When Compared to RT-qPCR in CML Patients Treated in the ENEST1st Trial

Reduced Expression of CD62L Is Associated with Increased ADAM17 Activity and Predicts Molecular Response to Nilotinib Therapy in Patients with Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP)

Low Level BCR-ABL Mutations and Response to Treatment: A Substudy of the ENEST1st Trial

Prognostic Value of Multi-Drug Resistance 1 Gene (MDR1) Expression in Newly Diagnosed Patients with Chronic Myeloid Leukemia on Nilotinib Treatment—a Subanalysis of the ENEST1st Study

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only